Bactheravax, advancing innovative colon cancer treatment becomes UNIIQ’s 100th investment
UNIIQ marked a major milestone: its 100th investment. The fund announced a new stake in Bactheravax, a UtrechtInc associated startup developing an innovative vaccine concept aimed at improving the treatment of colon cancer.
Colon cancer continues to have a significant societal impact, with high mortality rates despite advances in care. Bactheravax is working on a novel, research-driven approach that could strengthen treatment options and improve patient outcomes.
We congratulate Bactheravax and we look forward to seeing how they progress and contribute to the future of cancer treatment.